Skip to main content
Cureus logoLink to Cureus
. 2020 Jul 21;12(7):e9324. doi: 10.7759/cureus.9324

Pharmacological and Non-pharmacological Treatments of Irritable Bowel Syndrome and Their Impact on the Quality of Life: A Literature Review

Reham Gendi 1,, Nusrat Jahan 1
Editors: Alexander Muacevic, John R Adler
PMCID: PMC7444854  PMID: 32850202

Abstract

Irritable bowel syndrome (IBS) is a non-organic gastrointestinal disorder that adversely affects the quality of life (QoL). The etiology of the disease is not fully understood, and appropriate treatment is still a matter of debate. Therefore, we feel that a review that describes the different treatment methods of treatment is needed to provide the correct clues. A comprehensive literature search was performed on PubMed, including randomized clinical trials and review articles. We carefully reviewed the different treatment options mentioned in the published research papers and compared their results to address the treatment options for IBS. The current literature review reveals that pharmacological treatments such as antidepressants, vitamin D, probiotics, and antispasmodic drugs and non-pharmacological treatments including cognitive-behavioral therapy (CBT), acupuncture, anise, and diet modification can help control the symptoms of IBS and improve the QoL of patients.

Keywords: irritable bowel syndrome, physiology, pathology, epidemiology, psychology, therapy

Introduction and background

Irritable bowel syndrome (IBS) is a non-organic gastrointestinal disorder that has a negative impact on the quality of life (QoL). Currently, the diagnosis of IBS is based on new Rome IV criteria as a recurring abdominal pain related to two or more of the following conditions: defecation-related, associated with an increase in the stool frequency, and associated with a disparity in stool quality [1]. Symptom onset should occur at least six months before the diagnosis, and symptoms should be presented in the last three months, on average, and at least one day in a week.

The prevalence of IBS is approximately 9-23% worldwide, with a devastating impact on the QoL. Hence, we wanted to find out if IBS could be associated with psychological problems. The currently available treatment options, both pharmacological and non-pharmacological, can help in controlling symptoms. However, a knowledge gap still exists. We aim to find the best possible treatment options for IBS, which would help to treat this condition and improve the QoL for patients.

Mechanism of IBS

IBS symptoms have unclear etiology, and there is no specific treatment available to treat IBS patients. Recent studies show that symptoms of IBS most likely occur due to the gut-brain axis imbalance as evidenced by increased abdominal pain during periods of stress. Stress can cause a change in intestinal motility and permeability along with microbiota imbalance as some cases developed IBS due to alteration of the gut microbiota as a result of an infection [1,2-10]. In contrast, some believe it to be mostly caused by psychological disorders. According to Spiller et al., at least 50% of the IBS patients can be described as depressed, anxious, or hypochondriacs and over 60% of IBS patients receiving tertiary care had presented with a psychiatric disorder, most commonly depression, anxiety, or both [11].

Psychological disorders and their relation to IBS

Stress can modify and exacerbate central pain circuity and, therefore, it may be related to the development of visceral pain, which is related to IBS. A study has shown that IBS could be related to mental disorders as about 50-90% of IBS patients meet the criteria of psychiatric disorder, mainly anxiety, panic disorder, and major depressive disorder [12]. Another study has shown that catastrophizing, which is defined as expecting a negative outcome, is more common in IBS patients [13]. Hence, IBS can be associated with pain-catastrophizing thinking with a propensity to magnify the seriousness of the illness.

Treatment options

We are currently aware of the multi-systemic reasons behind the occurrence of IBS symptoms and the role of psychological disorders in its development or exacerbation. However, it needs to be further established as to how psychological treatment plans can be used as an effective way to resolve IBS symptoms. This psychosomatic visceral pain link can help us to illustrate several treatments that can help reduce symptoms in patients with IBS and improve their QoL.

The objective of this review is to focus on the treatment options for IBS and the effect of using different interventions to control IBS symptoms. It compares various studies discussing cognitive behavioral therapy (CBT), antidepressants, probiotics, anise, acupuncture, vitamin D, and diet modification as management options for IBS. The literature review aims to provide an insight into current treatment options for controlling IBS symptoms and improving the QoL.

Review

Materials and methods: data collection

The data were collected from PubMed using Medical Subject Headings (MeSH) keywords “Irritable bowel syndrome, physiology, pathology, epidemiology, psychology, and therapy.” The following inclusion criteria were applied in the order given; clinical trial and review studies, articles involving only human subjects, articles published in English only, and those involving subjects aged 19-44 years. The collection of the articles for the study was done in an ethical manner.

Results

Using MeSH keywords on PubMed, a total of 5,780 papers were collected, of which 651 were used for filtering. The details of the articles obtained by applying MeSH keywords and inclusion criteria in PubMed are given below (Table 1).

Table 1. Article search results on PubMed.

MeSH: Medical Subject Headings

Articles Results, n
Total article found on PubMed 13,950
Articles obtained with MeSH keywords 5,780
Clinical trials and reviews 2,221
Human subjects 2,215
English language 1,976
Subjects aged 19-44 651

Each of the 651 studies identified was evaluated individually based on the abstract. Among them, 163 articles were nonduplicated, and 67 were found to be non-relevant while screening the abstracts. Another 12 articles were excluded after the full-text screening since the patient age was out of the age range for our study. And one more article was removed during data extraction as it was a systemic review that included different age groups.

Finally, 83 relevant articles were chosen for this review article. The current literature review analyzes a total of 16 full-text articles that study different treatment options for controlling IBS symptoms.

Discussion

Although IBS is not a life-threatening condition, it puts a heavy burden on healthcare resources. Treating a patient for one year costs around $355-3,344, and the condition has a very drastic effect on the QoL of patients [14]. The condition has an unknown mechanism, and it has been found to alter intestinal motility and cause stress and microbiota imbalance, which explains the treatment options available now [1,2-10]. In this review, we included 83 papers on PubMed, which addressed the various treatment options available for IBS. We also engage in a comparison of these studies.

It has been found that many IBS patients respond to treatment to some extent. However, others do not due to various factors or the disparity in severity. In light of this, we review both pharmacological and non-pharmacological treatments that aimed to provide the best control of IBS symptoms and their effects on QoL. Our review aims to provide a complete overview of these treatment options to determine their efficacy in treating IBS in light of these previous studies.

Effect of Cognitive Behavioral Therapy on IBS

One study has discussed cognitive behavioral therapy (CBT) as a treatment option for controlling IBS symptoms compared with other possibilities as an educational exercise [15]. Another one has discussed its mechanism by drawing a connection between emotion, behavior, and cognition as a treatment option for IBS [16]. Overall, all these studies generally endorse using CBT for IBS (Table 2).

Table 2. Studies that discuss the effect of CBT on IBS.

CBT: cognitive behavioral therapy; IBS: irritable bowel syndrome; QoL: quality of life

Study Author name/year Study design Sample size Main points
Study 1 Lackner et al./2018 [15] Randomized controlled trial 436 patients The study compared CBT vs. education in the treatment of IBS. Patients were more responsive to CBT than education for IBS symptoms control
Study 2 Reme et al./2011 [16] Randomized controlled trial 149 patients This study supports that CBT has a positive impact on IBS symptoms due to communication between emotion, behavior, and cognition in the development of IBS
Study 3 Jang et al./2014 [17] Randomized controlled trial 180 patients initially; 13 patients withdrew during the research for various reasons The study showed the effect of CBT on IBS in female nursing students. CBT proved to be effective in improving QoL and reduced the symptoms of IBS
Study 4 Chilcot et al./2013 [18] Randomized controlled trial 64 patients The study showed CBT has a better effect on symptoms of IBS rather than usual treatment. CBT has a positive effect on IBS due to its impact on cognition rather than the mood
Study 5 Ljótsson et al./2013 [19] Randomized controlled trial 195 patients This study compared the impact of internet CBT and stress management on improving IBS symptoms. Internet CBT has a positive effect on IBS symptoms due to its ability to reduce gastrointestinal anxiety and not due to stress reduction
Study 6 Ljótsson et al./2010 [20] Randomized controlled trial 85 patients This study examined the role of CBT in developing mindfulness and exposure offered by the internet in controlling IBS symptoms. It showed that CBT via the internet is beneficial for controlling IBS symptom and improving patients’ QoL

Effect of Anti-psychological Pharmacological Treatment on IBS

Antidepressants and antipsychotic medications can be a treatment option for IBS. Many of the studies illustrate that some of these drugs, such as duloxetine, have shown a positive effect on patients with generalized anxiety disorder (GAD) along with IBS [21]. Tianeptine and amitriptyline have a positive impact on irritable bowel syndrome with diarrhea (IBS-D) [22]. Imipramine can also be used to treat IBS [23]. One study showed that citalopram could be useful while another study questioned this conclusion; both studies discussed the effect of citalopram on IBS symptoms away from its impact as an antidepressant (Table 3).

Table 3. Studies that discuss the effect of pharmacological treatment on IBS.

IBS: irritable bowel syndrome; IBS-D: irritable bowel syndrome with diarrhea; GAD: generalized anxiety disorder

Study Author name/year Study design Sample size Main points
Study 1 Kaplan et al./2013 [21] Pilot study 13 patients This study analyzes the effect of duloxetine in 13 patients with GAD and IBS. It found that duloxetine has a positive impact on IBS and GAD symptoms
Study 2 Sohn et al./2012 [22] Randomized clinical trial 228 patients This study compared the effect of tianeptine with amitriptyline on IBS. It used both medications in addition to probiotic. it concluded that both can improve IBS-D, but the side effects of tianeptine limit its use
Study 3 Abdul-Baki et al./2009 [23] Randomized, double-blind trial 56 patients Imipramine has a positive impact on IBS symptoms compared to placebo. It assists in improving QoL. Precaution by choosing the right candidate for its use is essential along with starting with low dose
Study 4  Ladabaum et al./2010 [24] Randomized clinical trial 54 patients The research concluded that citalopram does not have a positive effect on IBS symptoms in comparison to placebo in non-depressed patients
Study 5 Masand et al./2009 [25] Double-blind, randomized controlled study 72 patients Paroxetine has no beneficial effect on pain control in IBS, while it has a positive impact on clinical global impression improvement ratings
Study 6 Talley et al./2008 [26] Randomized controlled study 51 patients Neither imipramine nor citalopram has a positive effect on global IBS endpoints
Study 7 Tack et al./2006 [27] Double-blind, parallel-arm study 23 patients Citalopram has a positive impact on IBS symptoms. Citalopram’s positive effect is not related to improving depression or anxiety symptoms

Effect of Probiotics on IBS

One study has shown that probiotics could improve IBS symptoms, while another one has indicated that it might aggravate the IBS symptoms, specifically bloating [28,29]. We reviewed six studies relating to probiotics, and three of them showed that the probiotic effect is no stronger than that of placebo; one study showed that the probiotic effect on improving QoL is related to its impact on depression symptoms and not on IBS symptoms [30]. On the other hand, the other three showed that probiotics do have a positive effect on controlling IBS symptoms (Table 4).

Table 4. Studies that discuss the effect of probiotics on IBS.

IBS: irritable bowel syndrome; IBS-D: irritable bowel syndrome with diarrhea; QoL: quality of life

Study Author name/year Study design Sample size Main points
Study 1 Ishaque et al./2018 [28] Double-blind trial 400 IBS-D patients Probiotic has a beneficial effect on IBS-D symptoms, including abdominal pain and frequency of stool
Study 2 Pinto-Sanchez et al./2017 [30] Randomized, double-blind controlled study 44 IBS-D or mixed stool pattern patients Probiotic Bifidobacterium longum improves depression symptoms associated with IBS and QoL, which was accompanied by a change in a brain-stimulating pattern but does not affect IBS symptoms or the anxiety related to it
Study 3 Hod et al./2017 [31] Double-blind, placebo-controlled study 107 patients Probiotic BIO 25 has the same effect on IBS-D symptoms as a placebo
Study 4 Han et al./2016 [32] Randomized, double-blind controlled study 50 IBS-D patients The research compared the effect of a double coating or non-coating probiotic. It showed that double coating probiotic relieved IBS inconvenience and can be used as a treatment option for IBS-D
Study 5 Begtrup et al./2013 [33] Randomized controlled trial 131 patients The research compared the effect of probiotic-containing lactobacillus Paracasei, acidophilus and Bifidobacterium Bb12 to that of placebo through six months on controlling symptoms of IBS. The study did not detect a positive effect of probiotic when compared with placebo
Study 6 Enck et al./2009 [34] Double-blind controlled trial 298 patients The study compared the effects of probiotic Symbioflor-2 (E-Coli product) with that of placebo on abdominal pain score and showed that probiotic has a more significant effect than placebo

Effect of Other Treatment Options on IBS

There are plenty of other treatment options that might improve IBS symptoms. These options include a low fermentable oligo-, di-, mono-saccharides, and polyols (FODMAP) diet, anise, vitamin D, acupuncture, and antispasmodic drugs [35-39]. The following table provides the details of the studies that examined the effects of each of these options on controlling IBS symptoms (Table 5).

Table 5. Studies that discuss the effect of low FODMAP diet, anise, vitamin D, acupuncture, and antispasmodic drugs on IBS.

FODMAP: fermentable oligo-, di-, mono-saccharides, and polyols; IBS: irritable bowel syndrome; IBS-D: irritable bowel syndrome with diarrhea; NICE: National Institute for Health and Care Excellence

Study Author name/year Study design Sample size Main points
Study 1: FODMAP diet effect Eswaran et al./2016 [35] Randomized controlled trial 84 IBS-D patients The study compared the use of low FODMAP diet to modified NICE diet in controlling IBS symptoms and illustrated that low FODMAP diet has a significant effect on controlling pain and bloating compared to a diet based on the modified NICE guidelines
Study 2: anise effect Mosaffa-Jahromi et al./2016 [36] Three-armed, double-blind clinical trial 120 patients The study illustrated that the anise cap has a better impact on IBS symptoms improvement compared to ColperminTM or placebo
Study 3: vitamin effect Abbasnezhad et al./2016 [37] Double-blind, randomized, placebo-controlled trial 90 patients The study evaluated the effect of vitamin D compared to placebo on controlling IBS symptoms over six months. It showed that vitamin D has a more significant positive impact on improving IBS symptoms
Study 4: acupuncture effect MacPherson et al./2012 [38] Two-arm, pragmatic, randomized controlled study 233 patients The study compared acupuncture with usual care used in controlling IBS symptoms and illustrated that acupuncture has better results and should be a treatment option for IBS
Study 5: antispasmodic effect Zheng et al./2015 [39] Prospective, double-blind, placebo-controlled trial 427 patients in three hospitals in China Pinaverium has a better effect on improving IBS abdominal pain and stool frequency and can be considered a first-line treatment for IBS

Limitation of the study

Our literature review has some limitations. The study is limited in its analysis in terms of patient age (all patients involved were <45 years old) and does not include observational and non-randomized clinical trials. More studies are needed to explore the primary treatment of IBS to minimize its effects on QoL and reduce the burden on medical resources.

Conclusions

This literature review discussed the pharmacological and non-pharmacological treatment strategies for IBS based on previous studies. Based on our findings, we can conclude that the use of methods including CBT, anti-psychological medications, probiotics, and other approaches such as acupuncture, anise, and diet modifications can help control the symptoms of IBS and improve the QOL of patients. 

Acknowledgments

We would like to thank Hassan Tohid, neuroscientist and TEDx speaker, California Institute of Behavioral Neurosciences and Psychology, for his valuable contributions.

The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Footnotes

The authors have declared that no competing interests exist.

References

  • 1.Family history of mental illness or alcohol abuse and the irritable bowel syndrome. Knight JR, Locke GR 3rd, Zinsmeister AR, Schleck CD, Talley NJ. J Psychosom Res. 2015;78:237–241. doi: 10.1016/j.jpsychores.2014.11.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Bashashati M, Rezaei N, Shafieyoun A, et al. Neurogastroenterol Motil. 2014;26:1036–1048. doi: 10.1111/nmo.12358. [DOI] [PubMed] [Google Scholar]
  • 3.Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients. Rana SV, Sharma S, Sinha SK, Parsad KK, Malik A, Singh K. Trop Gastroenterol. 2012;33:251–256. doi: 10.7869/tg.2012.66. [DOI] [PubMed] [Google Scholar]
  • 4.Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Guilarte M, Santos J, de Torres I, et al. Gut. 2007;56:203–209. doi: 10.1136/gut.2006.100594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, et al. Gut. 2014;63:744–752. doi: 10.1136/gutjnl-2012-304066. [DOI] [PubMed] [Google Scholar]
  • 6.Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis. Ahn JY, Lee KH, Choi CH, et al. Dig Dis Sci. 2014;59:1001–1011. doi: 10.1007/s10620-013-2930-4. [DOI] [PubMed] [Google Scholar]
  • 7.Genome-wide association study identifies two novel genomic regions in irritable bowel syndrome. Holliday EG, Attia J, Hancock S, et al. Am J Gastroenterol. 2014;109:770–772. doi: 10.1038/ajg.2014.56. [DOI] [PubMed] [Google Scholar]
  • 8.Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Wouters MM, Lambrechts D, Knapp M, et al. Gut. 2014;63:1103–1111. doi: 10.1136/gutjnl-2013-304570. [DOI] [PubMed] [Google Scholar]
  • 9.Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Zhou Q, Zhang B, Verne GN. Pain. 2009;146:41–46. doi: 10.1016/j.pain.2009.06.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. Shulman RJ, Jarrett ME, Cain KC, Broussard EK, Heitkemper MM. J Gastroenterol. 2014;49:1467–1476. doi: 10.1007/s00535-013-0919-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Guidelines on the irritable bowel syndrome: mechanisms and practical management. Spiller R, Aziz Q, Creed F, et al. Gut. 2007;56:1770–1798. doi: 10.1136/gut.2007.119446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Whitehead WE, Palsson O, Jones KR. Gastroenterology. 2002;122:1140–1156. doi: 10.1053/gast.2002.32392. [DOI] [PubMed] [Google Scholar]
  • 13.Central processing of noxious somatic stimuli in patients with irritable bowel syndrome compared with healthy controls. Heymen S, Maixner W, Whitehead WE, Klatzkin RR, Mechlin B, Light KC. Clin J Pain. 2010;26:104–109. doi: 10.1097/AJP.0b013e3181bff800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Costs of irritable bowel syndrome in the UK and US. Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Pharmacoeconomics. 2006;24:21–37. doi: 10.2165/00019053-200624010-00002. [DOI] [PubMed] [Google Scholar]
  • 15.Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome. Lackner JM, Jaccard J, Keefer L, et al. Gastroenterology. 2018;155:47–57. doi: 10.1053/j.gastro.2018.03.063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Mediators of change in cognitive behaviour therapy and mebeverine for irritable bowel syndrome. Reme SE, Stahl D, Kennedy T, Jones R, Darnley S, Chalder T. Psychol Med. 2011;41:2669–2679. doi: 10.1017/S0033291711000328. [DOI] [PubMed] [Google Scholar]
  • 17.The effects of cognitive behavioral therapy in female nursing students with irritable bowel syndrome: a randomized trial. Jang AL, Hwang SK, Kim DU. Eur J Gastroenterol Hepatol. 2014;26:918–926. doi: 10.1097/MEG.0000000000000140. [DOI] [PubMed] [Google Scholar]
  • 18.Changes in illness-related cognitions rather than distress mediate improvements in irritable bowel syndrome (IBS) symptoms and disability following a brief cognitive behavioural therapy intervention. Chilcot J, Moss-Morris R. Behav Res Ther. 2013;51:690–695. doi: 10.1016/j.brat.2013.07.007. [DOI] [PubMed] [Google Scholar]
  • 19.Mechanisms of change in an exposure-based treatment for irritable bowel syndrome. Ljótsson B, Hesser H, Andersson E, et al. J Consult Clin Psychol. 2013;81:1113–1126. doi: 10.1037/a0033439. [DOI] [PubMed] [Google Scholar]
  • 20.Internet-delivered exposure and mindfulness based therapy for irritable bowel syndrome--a randomized controlled trial. Ljótsson B, Falk L, Vesterlund AW, et al. Behav Res Ther. 2010;48:531–539. doi: 10.1016/j.brat.2010.03.003. [DOI] [PubMed] [Google Scholar]
  • 21.An open-label trial of duloxetine in patients with irritable bowel syndrome and comorbid generalized anxiety disorder. Kaplan A, Franzen MD, Nickell PV, Ransom D, Lebovitz PJ. Int J Psychiatry Clin Pract. 2014;18:11–15. doi: 10.3109/13651501.2013.838632. [DOI] [PubMed] [Google Scholar]
  • 22.Tianeptine vs amitriptyline for the treatment of irritable bowel syndrome with diarrhea: a multicenter, open-label, non-inferiority, randomized controlled study. Sohn W, Lee OY, Kwon JG, et al. Neurogastroenterol Motil. 2012;24:860. doi: 10.1111/j.1365-2982.2012.01945.x. [DOI] [PubMed] [Google Scholar]
  • 23.A randomized controlled trial of imipramine in patients with irritable bowel syndrome. Abdul-Baki H, El Hajj II, Elzahabi L, et al. World J Gastroenterol. 2009;15:3636–3642. doi: 10.3748/wjg.15.3636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Ladabaum U, Sharabidze A, Levin TR, et al. Clin Gastroenterol Hepatol. 2010;8:42–48. doi: 10.1016/j.cgh.2009.09.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia IM, Patkar AA. Psychosomatics. 2009;50:78–86. doi: 10.1176/appi.psy.50.1.78. [DOI] [PubMed] [Google Scholar]
  • 26.Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Dig Dis Sci. 2008;53:108–115. doi: 10.1007/s10620-007-9830-4. [DOI] [PubMed] [Google Scholar]
  • 27.A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. Gut. 2006;55:1095–1103. doi: 10.1136/gut.2005.077503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome. [Apr;2020 ];Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-018-0788-9. BMC Gastroenterol. 2018 18:71. doi: 10.1186/s12876-018-0788-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet. Staudacher HM, Whelan K. Proc Nutr Soc. 2016;75:306–318. doi: 10.1017/S0029665116000021. [DOI] [PubMed] [Google Scholar]
  • 30.Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Pinto-Sanchez MI, Hall GB, Ghajar K, et al. Gastroenterology. 2017;153:448–459. doi: 10.1053/j.gastro.2017.05.003. [DOI] [PubMed] [Google Scholar]
  • 31.A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS. Hod K, Sperber AD, Ron Y, et al. Neurogastroenterol Motil. 2017;29 doi: 10.1111/nmo.13037. [DOI] [PubMed] [Google Scholar]
  • 32.Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial. Han K, Wang J, Seo JG, Kim H. J Gastroenterol. 2017;52:432–443. doi: 10.1007/s00535-016-1224-y. [DOI] [PubMed] [Google Scholar]
  • 33.Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE. Scand J Gastroenterol. 2013;48:1127–1135. doi: 10.3109/00365521.2013.825314. [DOI] [PubMed] [Google Scholar]
  • 34.Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. Enck P, Zimmermann K, Menke G, Klosterhalfen S. Z Gastroenterol. 2009;47:209–214. doi: 10.1055/s-2008-1027702. [DOI] [PubMed] [Google Scholar]
  • 35.A randomized controlled trial comparing the low FODMAP diet vs. modified NICE guidelines in US adults with IBS-D. Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. Am J Gastroenterol. 2016;111:1824–1832. doi: 10.1038/ajg.2016.434. [DOI] [PubMed] [Google Scholar]
  • 36.Efficacy and safety of enteric coated capsules of anise oil to treat irritable bowel syndrome. Mosaffa-Jahromi M, Lankarani KB, Pasalar M, Afsharypuor S, Tamaddon AM. J Ethnopharmacol. 2016;194:937–946. doi: 10.1016/j.jep.2016.10.083. [DOI] [PubMed] [Google Scholar]
  • 37.Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: a randomized double-blind clinical trial. Abbasnezhad A, Amani R, Hajiani E, Alavinejad P, Cheraghian B, Ghadiri A. Neurogastroenterol Motil. 2016;28:1533–1544. doi: 10.1111/nmo.12851. [DOI] [PubMed] [Google Scholar]
  • 38.Acupuncture for irritable bowel syndrome: primary care based pragmatic randomised controlled trial. [Apr;2020 ];MacPherson H, Tilbrook H, Bland JM, et al. https://bmcgastroenterol.biomedcentral.com/articles/10.1186/1471-230X-12-150. BMC Gastroenterol. 2012 12:150. doi: 10.1186/1471-230X-12-150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial. Zheng L, Lai Y, Lu W, et al. Clin Gastroenterol Hepatol. 2015;13:1285–1292. doi: 10.1016/j.cgh.2015.01.015. [DOI] [PubMed] [Google Scholar]

Articles from Cureus are provided here courtesy of Cureus Inc.

RESOURCES